MoonLake Immunotherapeutics is a clinical-stage biotechnology company developing therapies for inflammatory skin and joint diseases. The company focuses on sonelokimab, a tri-specific Nanobody that inhibits IL-17A and IL-17F. This molecule was discovered by Ablynx, a Sanofi company, and licensed from Merck KGaA. MoonLake is advancing sonelokimab for hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, palmoplantar pustulosis, and psoriasis. Clinical trials are conducted in the United States and Europe, with regulatory interactions involving the FDA and EMA. The pipeline includes Phase 3 trials for hidradenitis suppurativa and psoriatic arthritis, and Phase 2 trials for other indications. A Biologics License Application for hidradenitis suppurativa is expected in 2026, with a planned commercial launch in the United States in 2027.

Summarised from the company's own disclosures, fiscal year ended Feb 2026

Industry Biotechnology Homepage moonlaketx.com
Sector Healthcare IR page ir.moonlaketx.com
Tags
nanobody, inflammatory diseases, hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, psoriasis, il-17 inhibition, dermatology, rheumatology, clinical-stage, sonelokimab, M1095, ALX-0761, Ablynx, Sanofi, Merck KGaA, MHKDG, Avillion, MIRA, VELA-1, VELA-2, VELA-TEEN, ARGO, IZAR-1, IZAR-2, P-OLARIS, LEDA, S-OLARIS
Press page —

Metrics

Valuation  
Market cap $ 995.748M
Market cap (USD) $ 995.748M
P/E -3.18
PEG —
P/BV 2.61
P/S —
P/OCF -4.08
P/FCF -4.08
Dividend yield —
Turnover / mcap —
Returns  
ROE -60.5%
ROI -60.0%
ROIC -48.5%
Profit margin —
Growth  
Revenue growing —
Profits growing No
Revenue up 3y —
Revenue up 5y —
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable No
Margin expanding —
Buying back stock No
Diluting (TTM) Yes
Debt/Equity 26.2%
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 40
Quality score -75.0%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022
Assets 424.433M 477.933M 526.54M 76.843M
Net profit -227.318M -118.936M -36.007M -49.973M
Free cash flow -196.042M -117.107M -43.063M -55.91M

Figure FY 2025 FY 2024 FY 2023 FY 2022
Share price 13.18 54.15 60.39 10.5
Price performance 12m -0.76 -0.1 4.75 0.06

Filed figures

Figure Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Borrowings, current (USD) — 15M 0.00 — — —
Lease liabilities (USD) — 0.00 282,580 3.7M 2.83M 1.61M
Cash and deposits (USD) 1.34M 666,790 39.5M 451M 180M 335M
Right-of-use assets (USD) — 0.00 282,580 3.63M 2.92M 1.57M
Net debt (borrowings + leases - cash) (USD) — 6.96M -39.2M — — —
Cash flow detail
Operating cash flow (USD) — -611,071 -55.9M -42.8M -117M -196M
Purchases of property, plant and equipment (USD) — — -16,009 -284,634 -519,520 -35,000
Change in payables (cash effect) (USD) — 3.8M -1.31M 1.58M 7.15M 20.6M
Share buybacks (cash effect) (USD) — — 0.00 0.00 -50.00 —
Interest paid (cash effect) (USD) — — — 0.00 0.00 -5.06M
Income taxes paid (cash effect) (USD) — — -4,312 -41,713 -147,294 -799,000
Share-based compensation (USD) — — 9.65M 7.11M 7.28M 12.9M
Free cash flow (OCF - PPE - intangibles) (USD) — — -55.9M -43.1M -117M -196M
Income detail
Research and development expense (USD) — — 42M 31.8M 113M 203M
Total comprehensive income (USD) — — -63.8M -42.1M -119M -235M
Comprehensive income to owners (USD) — — -49.4M -34.5M -116M -232M
Reported Mar 31, 2021 Mar 20, 2023 Feb 26, 2025 Feb 25, 2026 Feb 25, 2026 Feb 25, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

•Biologics License Application for sonelokimab submitted to the U.S. Food and Drug Administration for the treatment of adults and adolescents with moderate-to-severe hidradenitis suppurativa, marking an important step towards potential U.S. approval and commercialization

•Positive Week 16 results from the Phase 3 IZAR-1 trial in psoriatic arthritis reported, with all clinical endpoints met for sonelokimab 60 mg with induction

•Enrollment completed in the Phase 3 IZAR-2 trial in psoriatic arthritis, with initial topline results expected in Q1 2027 following the predefined unblinding protocol

•Phase 3 NOVA trial in palmoplantar pustulosis on track to start enrollment in November 2026

•MoonLake ended the third quarter with $498.5 million in cash, cash equivalents and short-term marketable debt securities and expects to have a cash runway to mid-2028; additionally, up to $400 million in non-dilutive funds remain available through its debt facility with Hercules Capital

ZUG, Switzerland, November 4, 2026 – MoonLake Immunotherapeutics (NASDAQ: MLTX) ("MoonLake" or the "Company"), a clinical-stage biotechnology company focused on creating next-level therapies for inflammatory disease

MoonLake Immunotherapeutics — Other Events Bull 5 Bear 0 Clinical/regulatory

On September 30, 2026, MoonLake Immunotherapeutics (the “Company”) submitted a Biologics License Application (“BLA”) to the U.S. Food and Drug Administration (“FDA”), seeking approval of its tri-specific nanobody sonelokimab for the treatment of moderate-to-severe hidradenitis suppurativa in adults and pediatric patients 12 years of age and older. The Company expects to be notified by the FDA whether the BLA submission is accepted for review within approximately 60 days of submission, and to receive the planned review timeline within approximately 74 days of submission.

Cautionary Statement Regarding Forward-Looking Statements

This Current Report on Form 8-K contains certain “forward-looking statements” within the meaning of the U.S. Private Securities Litigation Reform Act of 1995.

Prompts

MoonLake Immunotherapeutics (ticker MLTX), listed in United States.

Company History

Date Change Detail
Apr 7, 2022 Renamed HELIX ACQUISITION CORP → MOONLAKE IMMUNOTHERAPEUTICS

ETFs Holding MoonLake Immunotherapeutics

ETF Weight in ETF Shares Market value As of
TMED 0.66% 7,823 $ 152.314K Jun 30, 2026
TCAF 0.03% 295,096 $ 3.461M Nov 17, 2026
AVSC 0.00% 378 $ 4,433.94 Nov 16, 2026